TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 174 filers reported holding TRAVERE THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 1.74 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,942,443 | -41.8% | 552,846 | 0.0% | 1.32% | -22.9% |
| Q2 2023 | $8,491,715 | +20.4% | 552,846 | +76.3% | 1.71% | -6.7% |
| Q1 2023 | $7,053,809 | +19.1% | 313,642 | +11.3% | 1.83% | +19.3% |
| Q4 2022 | $5,924,382 | -13.0% | 281,711 | +1.9% | 1.54% | -4.7% |
| Q3 2022 | $6,812,000 | +1.1% | 276,460 | -0.5% | 1.61% | -13.8% |
| Q2 2022 | $6,735,000 | -6.0% | 277,950 | 0.0% | 1.87% | -2.7% |
| Q1 2022 | $7,163,000 | -19.8% | 277,950 | -3.5% | 1.92% | +18.0% |
| Q4 2021 | $8,936,000 | +20.2% | 287,893 | -6.1% | 1.63% | +41.3% |
| Q3 2021 | $7,433,000 | – | 306,515 | – | 1.15% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Lynx1 Capital Management LP | 411,680 | $10,609,000 | 9.85% |
| VR Adviser, LLC | 1,994,997 | $51,411,000 | 8.33% |
| Kynam Capital Management, LP | 870,918 | $22,444,000 | 7.28% |
| GREAT POINT PARTNERS LLC | 1,010,000 | $26,028,000 | 6.29% |
| Deep Track Capital, LP | 3,134,503 | $80,776,000 | 5.18% |
| RA Capital Management | 4,922,941 | $126,864,000 | 2.77% |
| ARMISTICE CAPITAL, LLC | 4,958,000 | $127,768,000 | 2.47% |
| MPM BioImpact LLC | 277,950 | $7,163,000 | 1.92% |
| Sofinnova Investments, Inc. | 658,249 | $16,963,000 | 1.29% |
| Perceptive Advisors | 1,845,555 | $47,560,000 | 0.95% |